Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 19, 2026
Reporting period
Not applicable
Filed with the SEC
May 21, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references dividend reinvestment
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000318154-26-000106
Filed / recorded
May 21, 2026, 11:05 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
AMGEN INC
Issuer CIK
318154
Ticker
AMGN
Reporting person
Mary E. Klotman
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
May 19, 2026
Transaction code
A
Shares / units
665
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
2,211
Ownership form
Direct
Amendment
No
Footnotes from the filing
The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
These shares include 18 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.